Florida CBD Market Insights under Farm Bill

Mar.04.2023
Florida CBD Market Insights under Farm Bill
Florida's CBD market grows after the "Farm Bill" passed in 2018, but regulations remain a challenge for industry insiders like Jordan.

Statement:


This article is solely focused on conducting research on related industries and foreign markets. It does not recommend any specific products and does not comment on any domestic policies related to the subject matter.


The legality of the products mentioned in the article only applies to their local overseas markets. Domestic readers are advised to take note and strictly adhere to relevant laws and regulations in China.


This article does not constitute any investment or consumption advice.


This article is not suitable for minors.


On the first day of the Asia Pacific Expo, 2FIRSTS conducted an exclusive interview with Jordan, a representative for CBD dealers in Florida. Jordan provided insights into the CBD market in the state of Florida.


The "Farm Bill" promotes the development of the marijuana market.


In 2014, the state of Florida passed the "Compassionate Medical Cannabis Act," which allowed some patients to use medical marijuana and low-THC cannabis.


What has truly fueled the booming CBD market in Florida is the Farm Bill introduced by the United States in 2018.


According to Jordan, this bill essentially opens the door for certain requirements to be met by marijuana products, with the most noteworthy aspect being the release of cannabinoids, including non-psychoactive cannabidiol (CBD), from federal regulation.


Jordan emphasized a key point to 2FIRSTS, stating that as long as the Delta-9 THC content is below 0.3%, it is classified as hemp rather than marijuana.


After the enactment of this law, products can be legally manufactured, sold, and transported as long as they comply with the federal regulations on ingredients limits and labeling requirements.


However, the implementation of regulations in different states may vary. For example, Florida has stricter regulations regarding marijuana. "First, one must have a lab that has a QR code to test all substances in the sample, including the levels of THC and CBD in marijuana, as well as testing for mold, heavy metals, and pesticides," said Jordan.


You never know when new regulations may be implemented.


Although there are existing regulations at the macro level, government regulation in response to the development of the CBD market is not set in stone and will be adjusted over time as new issues arise. For distributors like Jordan, it is important to ensure clear and transparent product ingredients and avoid any gray areas or potential bans.


Jordan stated, "Because you never know when there will be new regulations. The regulatory authorities could change the rules as early as tomorrow.


In recent years, the United States has become increasingly tolerant towards recreational marijuana. Jordan himself holds an optimistic view towards the potential future legalization of recreational marijuana in Florida, believing that it's only a matter of time. Data seems to support his optimistic outlook - as of February 2023, 21 states and Washington D.C. have legalized recreational marijuana, a stark contrast to the zero states that had done so prior to November 2011.


How will the market develop in the future?


From the perspective of someone who is focusing on CBD products, the rapid changes in the US consumer market are even difficult for industry insiders to predict. He cited the example of the rise of psychedelic mushrooms in the US market last year. Prior to this, there had never been such a product on the market, and no one could have predicted the emergence of this dark horse.


Jordan stated, "The industry is increasingly turning to psychedelic mushrooms and other alternative smoking products, while consumers are also placing greater attention on health.


According to Jordan, the CBD market in Florida has great potential for growth, especially with the gradual relaxation of marijuana regulations and increased awareness among consumers of health benefits. This may lead to an emergence of more innovative products and demand in the market.


However, for industry professionals, the challenge of operating in a constantly changing regulatory environment remains significant. Regardless of how the market may shift in the future, Jordan states that his focus will always be on providing high-quality CBD products to consumers.


2FIRSTS will continue to cover the APE exhibition and we look forward to bringing you the latest updates and reports.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
The U.S. Department of Health and Human Services has named Bret Koplow permanent director of the FDA’s Center for Tobacco Products, ending his period as acting chief. Koplow has spent years working on tobacco regulation, law and policy inside the FDA and, while serving as acting director, pushed for faster PMTA reviews and nicotine pouch review pilots. HHS also said CTP will prioritize innovation and access to less harmful alternatives for adult smokers while continuing efforts to protect youth.
Sep.09
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
2Firsts Data | China’s Vape-Related Exports Rise 16.5% in July 2026 as U.S.-Bound Shipments Jump 53.5%
2Firsts Data | China’s Vape-Related Exports Rise 16.5% in July 2026 as U.S.-Bound Shipments Jump 53.5%
China’s vape-related exports reached $1.047 billion in July 2026, up 16.5% year on year and the highest monthly total of the year. Growth was heavily concentrated in the U.S., where exports jumped 53.5% to $404 million and accounted for 94.9% of the overall increase. Exports to all other markets rose just 1.2%. By category, nicotine-containing non-combustible products—primarily vapes—under HS24041200 rose 24.7% and generated 95.5% of the total increase. Vape-device exports under HS85434000 fell 0.4%, while other nicotine-substitute products under HS24041990 grew 88.9% but remained comparatively small.
DATA
Aug.24
FDA Grants PMTA Authorization to 11 ZYN ULTRA Nicotine Pouches, Bringing Total Authorized Pouches to 43
FDA Grants PMTA Authorization to 11 ZYN ULTRA Nicotine Pouches, Bringing Total Authorized Pouches to 43
The U.S. Food and Drug Administration authorized 11 ZYN ULTRA nicotine pouch products made by Swedish Match USA through the premarket tobacco product application pathway on August 21, 2026. Ten of the authorized products have a labeled nicotine content of 9 mg, while ZYN ULTRA Smooth was authorized at 11 mg. The reviews were conducted through FDA’s nicotine pouch PMTA pilot program. FDA has now authorized 43 nicotine pouch products, including 23 through the pilot.
Aug.24
Product | RELX Partners With UK E-Liquid Brand T-Juice for Prime Pro × Red Astaire Bundle in France
Product | RELX Partners With UK E-Liquid Brand T-Juice for Prime Pro × Red Astaire Bundle in France
RELX and UK e-liquid brand T-Juice have launched the Prime Pro × Red Astaire bundle in France, combining the RELX Prime Pro open-system pod device with T-Juice’s signature Red Astaire nicotine salt e-liquid. The collaboration retains the existing Prime Pro hardware platform while using an established flavor brand to create a complete open-system offering. The product appeared in French retail and distribution channels in August 2026 and represents a co-branded retail bundle rather than a new device launch.
Aug.27
Latest UK ONS Data: Vaping Rate Edges Down to 9.9% in 2025, a Year After Overtaking Cigarette Smoking
Latest UK ONS Data: Vaping Rate Edges Down to 9.9% in 2025, a Year After Overtaking Cigarette Smoking
Vaping prevalence in Great Britain edged down to 9.9% in 2025 from 10.0% in 2024, with the number of adult users holding at approximately 5.4 million for a second consecutive year, according to the Office for National Statistics (ONS). E-cigarette use had risen from 6.4% in 2020 to 10.0% in 2024, when it exceeded cigarette smoking prevalence for the first time. Cigarette smoking continued to decline to 8.7% in 2025, widening the gap to 1.2 percentage points. Daily vaping declined slightly, while usage among adults aged 25–34 increased despite falling rates in other age groups.
DATA
Oct.14